{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:04Z","timestamp":1753891864792,"version":"3.41.2"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer (NSCLC), which is resistant to conventional chemotherapy and radiotherapy with a poor prognosis. The MET inhibitor may be effective for the patients with MET exon 14 skipping mutation. This mutation was not detected in this patient. However, the PD-L1 TPS 60%, KRAS and TP53 mutations were detected in this patient could benefited from immunotherapy. The anlotinib is a novel multitarget antiangiogenic drug that could be effective for advanced non-small-cell lung cancer and some sarcoma patients. We report a patient with advanced pulmonary sarcomatoid carcinoma successfully treated with immunotherapy combined with antiangiogenic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 75-year-old male was admitted to the hospital in July 2020 because of productive cough for more than three months. The patient was diagnosed with advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis (cT4N3M1b, stage IVA) was treated in our hospital. Genetic testing revealed KRAS P.L19F mutation (abundance 19.12%) and NFEE2L2 P.E82G mutation (abundance 14.84%); TP53 P.S183 mutation (abundance 26.97%), TMB(Tumor Mutational Burden) 30.91 muts\/Mb, MSS, and PD-L1 (Daco 22C3) TPS 60% were also detected. We administrated sintilimab combined with anlotinib treatment, a PD-1 inhibitor with antiangiogenic drug. The patient achieved a favorable outcome with tolerable adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sintilimab combined with anlotinib treatment may lead to a favorable outcome for patients with advanced pulmonary sarcomatoid carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1167516","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:14:50Z","timestamp":1688148890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Gangyi","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuandong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.234682","article-title":"Pulmonary sarcomatoid carcinoma: university of Cincinnati experience","volume":"9","author":"Karim","year":"2018","journal-title":"Oncotarget"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.11.016","article-title":"Pulmonary sarcomatoid carcinoma: an analysis of the national cancer data base","volume":"18","author":"Steuer","year":"2017","journal-title":"Clin Lung Cancer"},{"article-title":"WHO classification of tumours","volume-title":"Thoracic tumours","year":"2021","key":"B3"},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.surg.2012.05.007","article-title":"Outcomes of sarco matoid carcinoma of the lung: a surveillance, epidemiol ogy, and end results database analysis","volume":"152","author":"Yendamuri","year":"2012","journal-title":"Surgery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000101","article-title":"Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma","volume":"39","author":"Lin","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/01.JTO.0000437008.00554.90","article-title":"Efficacy of first - line chemotherapy in patients with advanced lung sarcomatoid carcinoma","volume":"8","author":"Vieira","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"42428","DOI":"10.18632\/oncotarget.16403","article-title":"MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung","volume":"8","author":"Saffroy","year":"2017","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.005","article-title":"Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling","volume":"12","author":"Schrock","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0674","article-title":"Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations","volume":"34","author":"Liu","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.05.013","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages","volume":"98","author":"Vieira","year":"2016","journal-title":"Lung Cancer Amst Neth."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.014","article-title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma","volume":"12","author":"Domblides","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S212238","article-title":"Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer","volume":"11","author":"Liang","year":"2020","journal-title":"Cancer Manag Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1167516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:14:53Z","timestamp":1688148893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1167516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":14,"alternative-id":["10.3389\/fonc.2023.1167516"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1167516","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"article-number":"1167516"}}